Search Results

Background: The use of adjuvant chemotherapy following the surgical resection of pulmonary typical or atypical carcinoids has been highly debated. Guidelines currently indicate potential chemotherapy treatment for Stage IIIA disease in typical or

present, the NCCN Guidelines for Breast Cancer enumerate no fewer than 12 adjuvant chemotherapy regimens, with another 6 for HER2-positive disease. Each of these has been studied in phase III trials and has historical data to support its use. Some of these

population-based study demonstrated superior disease-free survival with addition of whole abdominal RT (WART) to 3 cycles of adjuvant chemotherapy in patients with stage II OCCC or a select subgroup of patients with stage IC disease (ICo) characterized by

-targeted therapies, such as trastuzumab. 3 – 5 However, outcomes for patients with HER2+ breast cancer treated outside of clinical trials are limited. 6 , 7 In small, node-negative, HER2+ tumors, the benefit of adding trastuzumab to adjuvant chemotherapy

cancer started chemotherapy more than 120 days after diagnosis, which is considered suboptimal care. 1 - 3 Similarly, data from the NCCN Oncology Outcomes Database showed a small proportion of patients with breast cancer who started adjuvant chemotherapy

Background : Triple-negative breast cancer (TNBC) is a subtype of breast cancer associated with an aggressive clinical course. Adjuvant chemotherapy has led to improved survival and decreased risk of recurrence with anthracycline and taxane

No definite preferred standard of care exists for adjuvant chemotherapy (ACT) in patients with node-negative, HER2-positive breast cancers measuring <2 cm. 1 Prior to the advent of HER2-directed therapy, HER2 overexpression was a marker of poor

hormone therapy and 88.8% with adjuvant chemotherapy and endocrine therapy. Her oncologist considered Oncotype DX (ODX) testing to help chemotherapy decision-making. Given the current emphasis on value-based practice, is ODX cost-effective for someone like

2006 ; 24 : 36 – 44 . 2 Maggi R Lissoni A Spina F . Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial . Br J Cancer 2006 ; 95 : 266 – 271 . 3 Alvarez Secord A Havrilesky LJ

guidelines, visit NCCN.org ). 11 The latter recommendation reflects findings from the CLASSIC trial; specifically, improved DFS and OS in patients receiving adjuvant chemotherapy (capecitabine/oxaliplatin) compared with those undergoing surgery alone. 11